IRIS
VERGARO, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.416
AS - Asia 13.546
EU - Europa 12.714
SA - Sud America 3.219
Continente sconosciuto - Info sul continente non disponibili 372
AF - Africa 346
OC - Oceania 29
Totale 57.642
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.854
SG - Singapore 4.724
IT - Italia 4.207
CN - Cina 3.305
RU - Federazione Russa 3.206
BR - Brasile 2.513
VN - Vietnam 1.926
GB - Regno Unito 1.446
BD - Bangladesh 1.056
HK - Hong Kong 951
CA - Canada 924
DE - Germania 831
FR - Francia 509
UA - Ucraina 471
SE - Svezia 429
FI - Finlandia 336
IN - India 327
IE - Irlanda 272
AR - Argentina 251
MX - Messico 250
NL - Olanda 211
TR - Turchia 187
PL - Polonia 183
ID - Indonesia 170
ES - Italia 138
IQ - Iraq 137
EC - Ecuador 127
ZA - Sudafrica 126
DK - Danimarca 123
IL - Israele 120
JP - Giappone 119
PK - Pakistan 99
CO - Colombia 88
AT - Austria 84
CR - Costa Rica 65
VE - Venezuela 63
UZ - Uzbekistan 61
MA - Marocco 57
AE - Emirati Arabi Uniti 54
LT - Lituania 52
PY - Paraguay 47
GT - Guatemala 46
HN - Honduras 45
CL - Cile 44
SV - El Salvador 38
TT - Trinidad e Tobago 37
PE - Perù 36
SA - Arabia Saudita 36
PR - Porto Rico 35
PH - Filippine 34
MY - Malesia 32
EG - Egitto 31
NI - Nicaragua 31
KE - Kenya 29
TN - Tunisia 29
CH - Svizzera 27
JM - Giamaica 24
UY - Uruguay 23
AZ - Azerbaigian 22
DZ - Algeria 22
BO - Bolivia 21
EU - Europa 21
BE - Belgio 20
JO - Giordania 20
NP - Nepal 20
AU - Australia 18
CW - ???statistics.table.value.countryCode.CW??? 17
GP - Guadalupe 17
KZ - Kazakistan 16
RO - Romania 16
AL - Albania 14
DO - Repubblica Dominicana 14
OM - Oman 13
TH - Thailandia 13
CZ - Repubblica Ceca 12
TW - Taiwan 12
PA - Panama 11
SK - Slovacchia (Repubblica Slovacca) 11
AM - Armenia 10
GR - Grecia 10
HU - Ungheria 10
IR - Iran 10
PT - Portogallo 9
BB - Barbados 8
BY - Bielorussia 8
KW - Kuwait 8
LB - Libano 8
MC - Monaco 8
NZ - Nuova Zelanda 8
PS - Palestinian Territory 8
BG - Bulgaria 7
MD - Moldavia 7
SN - Senegal 7
BH - Bahrain 6
CG - Congo 6
ET - Etiopia 6
GE - Georgia 6
HR - Croazia 6
KR - Corea 6
LV - Lettonia 6
Totale 57.174
Salva come PNG Salva come JPEG
Città #
Dallas 4.556
Singapore 2.472
San Jose 1.910
Ashburn 1.826
Chicago 1.323
Beijing 1.273
Council Bluffs 1.183
Los Angeles 1.163
Hong Kong 880
Ho Chi Minh City 614
Moscow 588
Milan 579
Salt Lake City 558
Southend 540
New York 539
Buffalo 478
Chandler 453
Fairfield 416
Rome 385
Hanoi 380
Houston 362
Santa Clara 358
Woodbridge 335
San Mateo 332
Tampa 315
Wilmington 290
The Dalles 287
Seattle 285
Phoenix 279
São Paulo 267
Dublin 258
Elk Grove Village 251
Ann Arbor 243
Cambridge 243
Falls Church 232
Lauterbourg 231
Boardman 222
Hefei 221
Helsinki 208
Ottawa 200
Jacksonville 195
Pisa 170
Montreal 167
Dearborn 162
Beauharnois 156
Portsmouth 156
Warsaw 155
Orem 153
Florence 145
Munich 142
Stevenage 142
Brooklyn 130
Naples 125
Sterling 124
Mexico City 121
Frankfurt am Main 119
Dong Ket 117
Lancaster 117
London 117
Atlanta 109
Toronto 108
Lawrence 107
Miami 106
Tel Aviv 104
Denver 103
Tokyo 101
Poplar 93
Amsterdam 92
Istanbul 90
Chennai 87
Rio de Janeiro 87
Johannesburg 84
Stockholm 81
Bologna 80
Da Nang 78
Nuremberg 78
Columbus 73
Turin 73
Dulles 72
Washington 65
Palermo 63
Detroit 62
San Diego 60
Haiphong 59
Figino 58
Manchester 58
Belo Horizonte 57
Boston 56
Tashkent 56
Kansas City 55
Genoa 54
Lappeenranta 53
Charlotte 48
Turku 48
Bari 47
Brasília 47
San Francisco 47
San José 47
Baghdad 44
Quito 44
Totale 33.182
Salva come PNG Salva come JPEG
Nome #
Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study 1.863
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis 1.732
Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology 1.609
High prevalence of wild-type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study 752
Valutazione delle caratteristiche analitiche e dei risultati clinici di un metodo in chemiluminescenza a cattura di microparticelle (CMIA) per il dosaggio della Galectina-3 sulla piattaforma ARCHITECT 712
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study 633
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 484
[18F]-Florbetaben PET/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions 435
A simple echocardiographic score to rule out cardiac amyloidosis 432
A simple echocardiographic score to rule out cardiac amyloidosis 412
Trastuzumab cardiotoxicity and drug cardioprotection in healthy and cardiac dysfunction mouse models 401
The heart failure specialists of tomorrow: a network for young cardiovascular scientists and clinicians 396
Markers of fibrosis, inflammation, and remodeling pathways in heart failure 350
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 350
Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging 343
[18F]-florbetaben PET/CT is sensitive for cardiac AL amyloidosis 337
Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches 334
Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis 333
Adrenergic activation in heart failure: blockade or rebalance? 326
Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation 326
Clinical and prognostic significance of central and obstructive apnoeas in patients with transthyretin cardiac amyloidosis 325
Eligibility for vericiguat in a real‐world, contemporary heart failure population 323
[Ten perspectives for research and innovation in cardiac amyloidosis] 319
Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy 316
[Rationale and significance of the Italian Network for Cardiac Amyloidosis] 315
Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis 315
CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy 315
Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure 314
A mechanistic look at sacubitril/valsartan action. Unravelling magician's secrets 314
RNA-targeting and gene editing therapies for transthyretin amyloidosis 313
Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis 313
A prognostically meaningful definition of non-dilated left ventricular cardiomyopathy 312
Screening the health status of people working in a university 305
Sex-related differences in chronic heart failure 302
How to take arms against central apneas in heart failure 301
Cheyne-Stokes respiration related oscillations in cardiopulmonary hemodynamics in patients with heart failure 301
Approach to the diagnosis and management of patients with cardiac amyloidosis. A consensus document by the Tuscan section of the Italian Association of Hospital Cardiologists (ANMCO) and the Tusco-Umbrian section of the Italian Society of Cardiology (SIC) 300
Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure 297
A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization - the first insight from the AC-TIVE Study 296
Central And Obstructive Apneas in Heart Failure With Reduced, Mid-Range And Preserved Ejection Fraction. 294
Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction 292
Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure 291
NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure 288
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study 287
Cardiac light-chain deposition disease relapsing in the transplanted heart 285
Contribution of the lung to the genesis of cheyne-stokes respiration in heart failure: Plant gain beyond chemoreflex gain and circulation time 283
Prognostic significance of myocardial extracellular volume fraction in nonischaemic dilated cardiomyopathy 282
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure 282
Cardiac magnetic resonance findings and prognosis in type 1 myotonic dystrophy 280
Clinical relevance of non-cardiac determinants of natriuretic peptide levels. 280
Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice 280
Atrial amyloidosis: mechanisms and clinical manifestations 279
Are big data on myocardial infarction enough for small heart failure patients? Lessons from a national registry 278
Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism 276
Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible? 275
Update sui biomarcatori nello scompenso cardiaco. 273
Biomarkers for the diagnosis and management of heart failure 273
Biomarkers for the diagnosis and management of heart failure: New frontiers 272
Disease features and management of cardiomyopathies in women 271
Valve disease in cardiac amyloidosis: an echocardiographic score 270
Biomarkers for the diagnosis and management of heart failure: Natriuretic peptides 266
Percorsi diagnostico-terapeutici assistenziali per i pazienti con amiloidosi cardiaca – Documento di consenso SIC/ANMCO. A cura della Rete Italiana dell’Amiloidosi Cardiaca (RIAC) 264
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology 262
[Diagnostic-therapeutic care pathways for patients with cardiac amyloidosis - SIC/ANMCO Consensus document. Edited by the Italian Cardiac Amyloidosis Network (RIAC)] 261
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 260
Discharge FGF23 level predicts one year outcome in patients admitted with acute heart failure 260
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis 259
In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation 259
null 258
Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study 258
Renin profiling predicts neurohormonal response to sacubitril/valsartan 258
The search for efficient diagnostic and prognostic biomarkers of heart failure 255
Role of Imaging in Cardiomyopathies 254
null 253
Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images 251
Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction 251
Early diagnosis, disease stage and prognosis in wild‐type transthyretin amyloid cardiomyopathy: The DIAMOND study 249
Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly? 248
Valvular heart disease in patients with cardiac amyloidosis 247
Predicting readmissions after hospitalization for heart failure: Medical reasoning vs calculators 247
Current and emerging treatment options for transthyretin amyloid cardiomyopathy 243
Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis 243
Effects of sacubitril-valsartan on remodelling, fibrosis and mitochondria in a murine model of isoproterenol-induced left ventricular dysfunction 242
Cardiac Amyloidosis: How Its Epidemiology is Changing 242
Correction of procedural arterial pseudoaneurysms: Established and novel procedures 242
Sacubitril–valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction 240
Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies 239
The IL-33/ST2 pathway, inflammation and atherosclerosis: Trigger and target? 239
Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient 239
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant 238
Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis 238
Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions 237
Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study 237
Prognostic value of plasma Renin activity in heart failure. 237
Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance 237
Beta-blocking patients with cardiac amyloidosis: Adelante cum juicio 236
The Role of Scintigraphy with Bone Radiotracers in Cardiac Amyloidosis 236
Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings 235
Central Apneas Are More Detrimental in Female Than in Male Patients With Heart Failure 235
Cardiac amyloidosis: Innovations in diagnosis and treatment 234
Totale 34.236
Salva come PNG Salva come JPEG
Categoria #
all - tutte 272.723
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 272.723
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.394 0 0 0 198 75 69 202 338 142 199 36 135
2022/20231.348 110 112 62 143 166 178 36 120 253 30 83 55
2023/20241.338 76 36 239 102 73 120 105 65 51 75 55 341
2024/202513.757 112 134 492 202 421 496 1.194 2.132 818 1.995 3.124 2.637
2025/202629.429 1.464 4.071 3.936 3.830 2.783 1.795 2.691 1.329 1.783 1.903 2.013 1.831
2026/20275.079 769 909 1.722 1.679 0 0 0 0 0 0 0 0
Totale 57.642